Xponance Inc. raised its holdings in shares of QuidelOrtho Co. (NASDAQ:QDEL – Get Rating) by 5.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,322 shares of the company’s stock after acquiring an additional 344 shares during the quarter. Xponance Inc.’s holdings in QuidelOrtho were worth $452,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. First Horizon Advisors Inc. raised its holdings in QuidelOrtho by 2,580.0% during the 2nd quarter. First Horizon Advisors Inc. now owns 268 shares of the company’s stock valued at $26,000 after acquiring an additional 258 shares during the period. Parkside Financial Bank & Trust increased its holdings in shares of QuidelOrtho by 177.3% in the second quarter. Parkside Financial Bank & Trust now owns 305 shares of the company’s stock worth $30,000 after purchasing an additional 195 shares during the period. New Century Advisors LLC increased its holdings in shares of QuidelOrtho by 52.6% in the second quarter. New Century Advisors LLC now owns 351 shares of the company’s stock worth $34,000 after purchasing an additional 121 shares during the period. Eagle Bay Advisors LLC increased its holdings in shares of QuidelOrtho by 174.2% in the second quarter. Eagle Bay Advisors LLC now owns 351 shares of the company’s stock worth $34,000 after purchasing an additional 223 shares during the period. Finally, Islay Capital Management LLC increased its holdings in shares of QuidelOrtho by 14.5% in the second quarter. Islay Capital Management LLC now owns 1,035 shares of the company’s stock worth $101,000 after purchasing an additional 131 shares during the period. Institutional investors own 95.21% of the company’s stock.
QuidelOrtho Stock Down 5.1 %
QDEL opened at $86.16 on Tuesday. The business’s fifty day simple moving average is $88.17 and its 200 day simple moving average is $87.57. QuidelOrtho Co. has a 52 week low of $66.88 and a 52 week high of $131.88. The stock has a market cap of $5.69 billion, a PE ratio of 4.58 and a beta of 0.29. The company has a quick ratio of 1.04, a current ratio of 1.66 and a debt-to-equity ratio of 0.52.
Analyst Upgrades and Downgrades
QDEL has been the topic of several research analyst reports. Citigroup raised shares of QuidelOrtho from a “neutral” rating to a “buy” rating and upped their price target for the stock from $90.00 to $125.00 in a report on Monday, December 12th. UBS Group raised shares of QuidelOrtho from a “sell” rating to a “neutral” rating and set a $86.00 price target on the stock in a report on Friday, October 14th. StockNews.com began coverage on shares of QuidelOrtho in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Craig Hallum reduced their target price on QuidelOrtho to $173.00 in a research note on Wednesday, December 14th. Finally, JPMorgan Chase & Co. reduced their target price on QuidelOrtho from $100.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, November 3rd. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $122.00.
QuidelOrtho Company Profile
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
- Get a free copy of the StockNews.com research report on QuidelOrtho (QDEL)
- Does TJX Have More Room To Run Or Will It Sink Into New Base?
- What Does Amazon’s Acquisition of 1LifeMedical Mean To Investors?
- 3 Airline Stocks Taking Off in 2023
- Why Wall Street Has Bullish Targets on Target Stock
- What Macy’s Guidance Means For Retail
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.